2024
240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
SHERR J, HAGAN K, BHAK R, PETER M, NGUYEN H, WANG C, PAKALAPATI T, SHERWOOD J, GUPTA T, GAGLIA J, CORNELIUS E, CHAPMAN K, WOLF W, PETTUS J. 240-OR: Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey. Diabetes 2024, 73 DOI: 10.2337/db24-240-or.Peer-Reviewed Original ResearchFollow-up surveySevere hypoglycemic eventsImpaired awareness of hypoglycemiaOnline surveyT1D Exchange RegistryProportion of respondentsT1D careFollow-upEligible individualsHbA1c < 7%Diabetes technologyLongitudinal trendsCGM useHbA1c targetLongitudinal assessmentInsulin delivery methodsHbA1cAwareness of hypoglycemiaSurveyParticipantsImpaired awarenessAdultsT1DRespondentsHypoglycemic events
2023
Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results
Miller K, Bauza C, Kanapka L, Clements M, DeSalvo D, Hood K, Messer L, Sherr J, Bergamo K, Criego A, Freiner E, Lyons S, Monzavi R, Moore W, Prahalad P, Simmons J, Sulik M, Wadwa R, Weinstock R, Willi S, Williams K, Laffel L, Group F. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12‐Month Follow‐Up Results. Pediatric Diabetes 2023, 2023: 1-12. DOI: 10.1155/2023/6718115.Peer-Reviewed Original ResearchType 1 diabetesMedian percent timeUse of CGMBlood glucose monitoringYoung adultsCGM initiationExtension phaseGlucose monitoringPercent timeContinuous glucose monitoringMean hemoglobinGlycemic controlCGM groupUp ResultsClinical trialsGlycemic outcomesGlycemic benefitsCGM useMonitoring interventionsType 1Further evaluationBGM groupWeeksDlAdultsAdolescent‐ and Young Adult‐Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial
Messer L, Bauza C, Miller K, Clements M, DeSalvo D, Sherr J, Weinstock R, Hood K, Laffel L. Adolescent‐ and Young Adult‐Reported Outcomes and Use of Continuous Glucose Monitoring Features: A Report from the CITY Trial. Pediatric Diabetes 2023, 2023: 1-10. DOI: 10.1155/2023/6906023.Peer-Reviewed Original ResearchPittsburgh Sleep Quality IndexYoung adultsBlood glucose metersAdolescents/young adultsGood glycemic controlSleep Quality IndexDays/weekType 1 diabetesContinuous glucose monitor useUse of CGMContinuous glucose monitoringBenefits of CGMGlycemic controlCGM groupClinical trialsCGM useMedical outcomesBGM groupGlucose monitoringMonitor useWeeksConfidence ScaleEmotional healthGlucose dataAdults
2020
Changes in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange
Levy CJ, Foster NC, DuBose SN, Agarwal S, Lyons SK, Peters AL, Uwaifo GI, DiMeglio LA, Sherr JL, Polsky S. Changes in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange. Journal Of Diabetes Science And Technology 2020, 15: 1297-1302. PMID: 33218278, PMCID: PMC8655289, DOI: 10.1177/1932296820972123.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionPregnant womenEligible participantsCohort 2Continuous glucose monitorGlycemic outcomesT1D Exchange Clinic RegistryDevice useSubcutaneous insulin infusionHemoglobin A1c resultsT1D pregnancyGlycemic controlClinic registryT1D ExchangeCSII useA1C resultsInsulin infusionMedical recordsCohort 1CGM useType 1Device uptakeWomenSurvey completionAdditional evaluation
2019
215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes
BUCKINGHAM B, FORLENZA G, SHERR J, GALDERISI A, EKHLASPOUR L, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. 215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-215-or.Peer-Reviewed Original ResearchDiabetes careMedtronic MiniMedSevere hypoglycemic eventsChildren Aged 2Advisory PanelYoung childrenMin/dAge 4.2Oral carbohydrateHybrid closed-loop systemHypoglycemic eventsGlycemic outcomesMean glucoseAged 2CGM useTherapy phaseInvestigational deviceType 1T1D therapyPercent timeMiniMedLexicon PharmaceuticalsCareUsual routineAdult participants
2018
Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions
FORLENZA G, BUCKINGHAM B, SHERR J, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1376-p.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesMin/dAdvisory PanelHybrid closed-loop systemStandard therapyDays of useEligible participantsAge 14.3Percentage of timeCGM useInvestigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodAdolescentsConcomitant reductionSafety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions
SHERR J, FORLENZA G, BUCKINGHAM B, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1377-p.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesChildren Aged 6Min/dAdvisory PanelAge 9.9Hybrid closed-loop systemStandard therapyDays of useEligible participantsPercentage of timeCGM useAged 6Investigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodSafety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions
BUCKINGHAM B, SHERR J, FORLENZA G, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-207-or.Peer-Reviewed Original ResearchModerate-intensity exerciseDiabetes careGlycemic outcomesFree-living conditionsType 1 diabetesMin/dAdvisory PanelHybrid closed-loop systemStandard therapyDays of useEligible participantsPercentage of timeCGM useInvestigational deviceMedtronic MiniMedType 1DlTime 70Usual routineCareEli LillyOmnipodAdultsConcomitant reductionDays
2011
Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes
Tsalikian E, Fox L, Weinzimer S, Buckingham B, White NH, Beck R, Kollman C, Xing D, Ruedy K, Group D. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatric Diabetes 2011, 13: 301-307. PMID: 22151826, PMCID: PMC3665108, DOI: 10.1111/j.1399-5448.2011.00837.x.Peer-Reviewed Original ResearchConceptsType 1 diabetesParental satisfactionMultiple daily injectionsContinuous glucose monitoring useYr of ageYoung childrenContinuous glucose monitoringMean HbA1cMean hemoglobinGlycemic controlMonth 6Daily injectionsMean ageSkin reactionsBiochemical hypoglycemiaCGM useGlucose valuesGlucose readingsInsulin pumpHyperglycemic excursionsHyperglycemic rangeGlucose monitoringMonthsWkDiabetes